title: Intrathecal gabapentin increases interleukin-10 expression and inhibits pro-inflammatory cytokine in a rat model of neuropathic pain.
abstract: We examined the possible anti-inflammatory mechanisms of gabapentin in the attenuation of neuropathic pain and the interaction between the anti-allodynic effects of gabapentin and interleukin-10 (IL-10) expression in a rat model of neuropathic pain. The anti-allodynic effect of intrathecal gabapentin was examined over a 7-day period. The anti-allodynic effects of IL-10 was measured, and the effects of anti-IL-10 antibody on the gabapentin were assessed. On day 7, the concentrations of pro-inflammatory cytokines and IL-10 were measured. Gabapentin produced an anti-allodynic effect over the 7-day period, reducing the expression of pro-inflammatory cytokines but increasing the expression of IL-10 (TNF-α, 316.0 ± 69.7 pg/mL vs 88.8 ± 24.4 pg/mL; IL-1β, 1,212.9 ± 104.5 vs 577.4 ± 97.1 pg/mL; IL-6, 254.0 ± 64.8 pg/mL vs 125.5 ± 44.1 pg/mL; IL-10, 532.1 ± 78.7 pg/mL vs 918.9 ± 63.1 pg/mL). The suppressive effect of gabapentin on pro-inflammatory cytokine expression was partially blocked by the anti-IL-10 antibody. Expression of pro-inflammatory cytokines was significantly attenuated by daily injections of IL-10. The anti-allodynic effects of gabapentin may be caused by upregulation of IL-10 expression in the spinal cord, which leads to inhibition of the expression of pro-inflammatory cytokines in the spinal cords.
authors: Department of Anesthesiology and Pain Medicine, CHA Medical Center, CHA University, Gumi, Korea.
authors: Byung-Sang
authors: BS
authors: Lee
authors: In-Gu
authors: IG
authors: Jun
authors: Sung-Hoon
authors: SH
authors: Kim
authors: Jong Yeon
authors: JY
authors: Park
mesh_terms: D000588:Amines / Q000494:pharmacology / Q000627:therapeutic use*; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism*; D004195:Disease Models, Animal; D000077206:Gabapentin; D007278:Injections, Spinal; D016753:Interleukin-10 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D008297:Male; D009437:Neuralgia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology; D013116:Spinal Cord / Q000378:metabolism; D015854:Up-Regulation; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000588:Amines; D000700:Analgesics; D000906:Antibodies; D003509:Cyclohexanecarboxylic Acids; D016207:Cytokines; D011994:Recombinant Proteins; D016753:Interleukin-10; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin
keywords: Allodynia; Gabapentin; Interleukin-10; Intrathecal; Pro-inflammatory Cytokines
references: Pain. 1992 Sep;50(3):355-363
references: 1333581
references: Brain Res. 2005 Apr 25;1042(1):108-13
references: 15823259
references: J Neurosci Methods. 1994 Jul;53(1):55-63
references: 7990513
references: J Neurosci. 2002 Nov 15;22(22):9980-9
references: 12427855
references: J Korean Med Sci. 2008 Aug;23(4):678-84
references: 18756057
references: Nat Med. 2008 Mar;14(3):331-6
references: 18264108
references: J Pharmacol Exp Ther. 2003 Jan;304(1):102-8
references: 12490580
references: Brain Behav Immun. 2007 Feb;21(2):131-46
references: 17175134
references: Neuropsychopharmacology. 2008 Oct;33(11):2772-82
references: 18216775
references: Br J Pharmacol. 1997 Aug;121(8):1513-22
references: 9283683
references: JAMA. 1998 Dec 2;280(21):1831-6
references: 9846777
references: Pharmacol Ther. 2006 Jan;109(1-2):210-26
references: 16169595
references: Behav Brain Res. 2010 Feb 11;207(1):30-6
references: 19799935
references: Exp Brain Res. 1997 Feb;113(2):200-6
references: 9063706
references: Palliat Med. 2004 Jan;18(1):5-11
references: 14982201
references: Expert Opin Ther Targets. 2012 Jun;16(6):527-40
references: 22519838
references: Pain. 2006 Dec 15;126(1-3):294-308
references: 16949747
references: Brain Res Rev. 2006 Aug;51(2):240-64
references: 16388853
references: J Exp Med. 1989 Dec 1;170(6):2081-95
references: 2531194
references: Physiol Behav. 1976 Dec;17(6):1031-6
references: 14677603
references: Lancet. 1999 Jun 5;353(9168):1959-64
references: 10371588
references: Semin Cell Dev Biol. 2006 Oct;17(5):565-70
references: 17067834
references: Neuroimmunomodulation. 1995 May-Jun;2(3):149-54
references: 8646564
references: JAMA. 1998 Dec 2;280(21):1837-42
references: 9846778
references: Anesth Analg. 2012 Jun;114(6):1330-7
references: 22415536
references: J Pharmacol Exp Ther. 2002 Dec;303(3):1199-205
references: 12438544
references: Ann N Y Acad Sci. 2012 Jul;1262:101-7
references: 22823441
references: Brain Res. 1993 Apr 30;610(1):62-8
references: 8518931
references: Int Anesthesiol Clin. 2007 Spring;45(2):27-37
references: 17426506